NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Bioreactor Process Parameter Screening Utilizing a Plackett-Burman Design for a Model Monoclonal Antibody
Published
Author(s)
John E. Schiel, Cyrus D. Agarabi, Scott C. Lute, Brittany K. Chavez, Michael T. Boyne, Kurt A. Brorson, Mansoor A. Kahn, Erik K. Read
Abstract
Consistent high quality antibody yield is a key goal for cell culture bioprocessing. This endpoint is typically achieved in commercial settings through product and process engineering of bioreactor parameters during development. When the process is complex and not optimized, small changes in composition and control may yield a finished product of less than desirable quality. Therefore, changes proposed to currently validated processes usually require justification and are reported to the FDA for approval. Recently, Design of Experiments (DoE) based approaches have been explored to rapidly and efficiently achieve this goal of optimized yield with a better understanding of product and process variables that affect a products critical quality attributes. Here, we present a lab-scale model culture where we apply a Plackett-Burman screening design to parallel cultures to study the main effects of 11 process variables. This exercise allowed us to determine the relative importance of these variables and identify the most important factors to be further optimized. We found engineering changes relating to culture temperature and non-essential amino acid supplementation significantly impacted glycan profiles associated with fucosylation, β-galactosylation, and sialylation, which are important for monoclonal antibody product quality.
Schiel, J.
, Agarabi, C.
, Lute, S.
, Chavez, B.
, Boyne, M.
, Brorson, K.
, Kahn, M.
and Read, E.
(2015),
Bioreactor Process Parameter Screening Utilizing a Plackett-Burman Design for a Model Monoclonal Antibody, Journal of Pharmaceutical Sciences, [online], https://doi.org/10.1002/jps.24420
(Accessed October 18, 2025)